Basilea Pharmaceutica Presents Research Data at ICAAC on Novel Antibiotic Addressing the Emerging Threat from Multi-resistant Gram-negative Bacteri

BASEL, SWITZERLAND--(MARKET WIRE)--Sep 17, 2007 -- Multi-resistant Gram-negative bacteria have been appearing with increasing frequency around the world. Basilea’s antibiotic BAL30376 demonstrates a broad-spectrum in-vitro activity targeting multi-resistant Gram-negative bacteria.